Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Central serotonergic regulation could have a role in the course of pituitary-dependent Cushing's disease. We studied the effects of ritanserin and ketanserin, two related selective 5HT2 receptor antagonists, in 11 patients with Cushing's disease. Treatment lasted from 1 month to 1 year (up to 4 years in one patient). Daily doses were 10-15 mg for ritanserin, and 40-80 mg for ketanserin. Since the two drugs share the same mechanism of action and no qualitative or quantitative differences in response to their administration were observed, the results were pooled together. Patients were assessed by clinical and hormonal evaluation. Urinary cortisol and ACTH were considered the parameters of interest. Short-term response: after 1 month, there was a significant decrease of urinary cortisol from 781 (160) to 331 (215) nmol/d (P < 0.02) while ACTH was 9.8 (1.5) pmol/L baseline and again 8.8 (2.2) pmol/L at 1 month (P = NS). For 9 patients, hormonal parameters were available after 1 week of treatment. In this case, also ACTH levels were significantly decreased (from 9.6 (1.7) to 5.2 (1.3) pmol/L; P < 0.01) together with urinary cortisol (from 781 (194) to 372 (165) nmol/d; P < 0.01). Long-term response: in 3 patients, hormonal parameters failed to respond to serotonin receptor antagonists, which were thus discontinued. An improvement was recorded in the remaining 8 patients, that was prolonged in 3, and transient in 5. In 3 of these latter patients, a marked increase of ACTH was observed before treatment discontinuation. Ketanserin was given to 2 patients with Nelson's syndrome, with only transient ACTH decrease in one, and no changes in ACTH response to CRH after 1 month treatment in both cases. An inhibitory effect of ritanserin and ketanserin on ACTH and cortisol production in Cushing's disease appeared to be limited both in terms of duration of response and number of patients with a satisfactory outcome. However, the results may provide a better understanding of serotonergic modulation in Cushing's disease and lead to therapeutic developments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence a down-regulation of 5HT2 post-synaptic receptors which has been proposed as one of the final pathways driving therapeutic effects of different antidepressant [50] may facilitate 5HT1 receptor neurotransmission, which in turn may activate the HPA axis with an increased production of adrenocorticotropic hormone (ACTH) and cortisol [51].”
Citations
Cites
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,003
Role of 5-HT in stress, anxiety, and depression
Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02135-3 · Cited by 984 · cited 1×
“There is extensive preclinical evidence on the biphasic nature of the relationship between serotonin receptors and adrenal steroids [ 36 ].”
BackgroundLeysen, J. E., Gommeren, W., Van Gompel, P., Wynants, J., Janssen, P. F., & Laduron, P. M. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12558-3 · Cited by 452
Cyproheptadine-Induced Remission of Cushing's Disease
Krieger, D. T., Amorosa, L., & Linick, F. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510302931802 · Cited by 316 · cited 1×
“Krieger et al. [ 1 ] introduced the use of an antiserotonergic drug, cyproheptadine, in the treatment of Cushing’s disease.”
BackgroundThe Cushing Syndrome: An Update on Diagnostic Tests
Kaye, T. B., & Crapo, L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-434 · Cited by 310
Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function
Dinan, T. G. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00066-5 · Cited by 303
Risk factors and long-term outcome in pituitary-dependent Cushing's disease
Sonino, N. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2647 · Cited by 265 · cited 1×
“The differential diagnosis included high dose dexamethasone (signi~cant suppression occurred if cortisol at the end o the test had fallen to 50% or less of its basal levels) and CRH tests, and ACTH measurements [22, 23 ].”
BackgroundThe Medical Treatment of Cushing's Syndrome
MILLER, J. W., & CRAPO, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-443 · Cited by 202 · cited 1×
“Variable outcomes have been also observed with other neuromodulatory agents, such as bromocriptine, valproic acid and octreotide [ 2 ,3].”
ResultKetoconazole treatment in Cushing’s syndrome: experience in 34 patients
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., & Zillotto, D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03547.x · Cited by 201 · cited 1×
“Combination therapies with compounds inhibiting cortisol production at adrenal level, i.e. ketoconazole [3, 37 ], are also conceivable.”
BackgroundSelf-citationCALOGERO, A. E., BAGDY, G., SZEMEREDI, K., TARTAGLIA, M. E., GOLD, P. W., & CHROUSOS, G. P. (1990) · Endocrinology · doi:10.1210/endo-126-4-1888 · Cited by 164 · cited 1×
“The use of 5HT2A and 5HT2C receptor antagonists in Cushing’s disease might lead to 5HT1A receptors activation, which in turn is likely to stimulate ACTH release [ 30 ].”
Method
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
“-aminobutyric acid (GABA) agonists are generally ineffective and are not routinely recommended (86).”
BackgroundSelf-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Boscaro, M., Barzon, L., Fallo, F., & Sonino, N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04172-6 · Cited by 350
Sonino, N., & Fava, G. A. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00003 · Cited by 267
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
“corticotropic hormone (ACTH) and cortisol secretion, followed by an escape phenomenon.(100) An impressive body of evidence(101,102) supports the”
BackgroundAnticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome
Boscaro, M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3662 · Cited by 198
Medical Therapy of Cushing's Disease
Nieman, L. K. (2002) · Pituitary · doi:10.1023/a:1022308429992 · Cited by 185
“A similar response was seen in 3 of 11 patients who normalized urine cortisol during chronic treatment with the selective serotonin receptor antagonists ritanserin or ketanserin [ 6 ].”
BackgroundThe mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“An example of this interaction is provided by the use of specific 5HT2 receptor antagonists (ritanserin and ketanserin) in Cushing's disease, which often yield only a temporary decrease in ACTH and cortisol secretion, followed by an escape phenomenon (Sonino et al., 2000).”
Cohrs, S., Röher, C., Jordan, W., Meier, A., Huether, G., Wuttke, W., Rüther, E., & Rodenbeck, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0279-x · Cited by 141
“…(mCPP), on positive symptoms and plasma cortisol levels in schizophrenic patients (Abi Saab et al. 2002), and a reduction of cortisol levels after the administration of ritanserin has also been found in patients with Cushing’s disease (Sonino et al. 2000) and healthy subjects (Seibyl et al. 1991).”
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
The Medical Management of Cushing's Syndrome
MORRIS, D., & GROSSMAN, A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04418.x · Cited by 70
Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management
Banasiak, M., & Malek, A. R. (2007) · Neurosurgical FOCUS · doi:10.3171/foc-07/09/e13 · Cited by 50
Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects
Cohrs, S., Pohlmann, K., Guan, Z., Jordan, W., Meier, A., Huether, G., R�ther, E., & Rodenbeck, A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1766-6 · Cited by 47
“A reduction of cortisol levels after the administration of ritanserin has also been found in patients with Cushing’s disease (Sonino et al. 2000) and healthy subjects (Seibyl et al.”
BackgroundUpdate on medical treatment for Cushing’s disease
Ramos, D. C., Lim, D. S. T., & Fleseriu, M. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0033-9 · Cited by 48
“previously been studied in CD, but shown to have limited efficacy, and serious adverse effects [4, 77, 78].”
BackgroundPharmacologic Management of Cushing Syndrome: New Targets for Therapy
Sonino, N., Boscaro, M., & Fallo, F. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504020-00003 · Cited by 36
Molecular basis of pharmacological therapy in Cushing’s disease
Ferone, D., Pivonello, C., Vitale, G., Zatelli, M. C., Colao, A., & Pivonello, R. (2013) · Endocrine · doi:10.1007/s12020-013-0098-5 · Cited by 35
“However, besides the still unknown exact mechanism of action of this class of drugs, and the variability in the clinical outcome, the sedative side effects, as well as the orexigenic properties, strongly limited the use of anti-serotonergic drugs in the clinical practice [9, 13].”
BackgroundPharmacological management of Cushing's syndrome: an update
Dang, C. N., & Trainer, P. J. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800020 · Cited by 31
Liu, C., Zhang, X., Zhou, J., Wei, W., Liu, D., Ke, P., Zhang, G.-F., Cai, G., & Su, D. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.045 · Cited by 28
Casar‐Borota, O., Botling, J., Granberg, D. O., Stigare, J., Wikström, J., Boldt, H. B., Kristensen, B. W., Pontén, F., & Trouillas, J. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000908 · Cited by 30
“13,14 Moreover, the serotonin analogs may have, at least, temporary inhibitory effects on the synthesis and production of adrenocorticotroph hormone (ACTH) in patients with Cushing disease caused by corticotroph tumor.(15,16) From the Departments of *Immunology, Genetics and Pathology; yMedical Sciences; 8Surgical Sci…”
BackgroundNelson Syndrome: Update on Therapeutic Approaches
Azad, T. D., Veeravagu, A., Kumar, S., & Katznelson, L. J. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.01.038 · Cited by 20
“Valproic acid (2, 30, 35), rosiglitazone (21-23), and serotonin antagonists (57, 63) have been used in NS with limited success (45, 46).”
MethodPituitary-targeted medical therapy of Cushing's disease
Alexandraki, K., & Grossman, A. B. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.669 · Cited by 20
“In clinical studies, the response rate in patients treated with cyproheptadine or the similar metergoline has been poor, as it has also been to the more selective serotonin antagonists ritanserin and ketanserin [59,62-65].”
BackgroundTolerance to antidepressant treatment may be overcome by ketoconazole. Report of two cases
Sonino, N., & Fava, G. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00089-4 · Cited by 19
Residual symptoms in depression
Sonino, N., & Fava, G. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00200-2 · Cited by 23
New and emerging drug therapies for Cushing’s disease
Störmann, S., & Schopohl, J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1504021 · Cited by 18
“small study with 11 patients failed to show consistent and reproducible effects [79].”
BackgroundCorticotroph adenoma in the dog: Pathogenesis and new therapeutic possibilities
Castillo, V. A., & Gallelli, M. F. (2009) · Research in Veterinary Science · doi:10.1016/j.rvsc.2009.07.005 · Cited by 12
“such as cyproheptadine, ritanserin and ketanserin haven’t shown good results (Sonino et al., 2000; Arnaldi et al., 2007).”
BackgroundAdvances in the medical management of Cushing's syndrome
Giraldi, F. P., & Cavagnini, F. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.14.2423 · Cited by 9
“Indeed, ketanserin and ritanserin induced stable improvement in only 3 out of 11 patients with Cushing’s disease [41] .”
BackgroundKim, W., Cho, Y. A., Min, K. H., Kim, D. C., & Lee, K.-E. (2023) · Pharmaceuticals · doi:10.3390/ph16081097 · Cited by 7
“reported a significant decrease in cortisol levels after the administration of ritanserin [45].”
BackgroundMedical Therapy for Cushing’s Disease – Past and Future Modes of Treatment
Alexandraki, K., Grossman, A. B., & Endocrinology, S. I. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.74 · Cited by 5
Advances in medical treatment of Cushing’s disease
Arnaldi, G., Cardinaletti, M., & Boscaro, M. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.6.735 · Cited by 4
Juszczak, A., Morris, D. G., Grossman, A. B., & Nieman, L. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00013-5 · Cited by 6
Update on Hypercortisolism Therapy
Arnaldi, G., & Trementino, L. (2016) · Frontiers of hormone research · doi:10.1159/000443869 · Cited by 3
Management of Nelson’s Syndrome
Fountas, A., & Karavitaki, N. (2022) · Medicina · doi:10.3390/medicina58111580 · Cited by 3
“Similar results were reported for ketanserin, another serotonin antagonist, which was ineffective in the suppression of ACTH levels in patients with NS [85,86].”
ResultCushing’s Disease: Medical Management
Lindsay, J. R., & Nieman, L. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-264-9_12 · Cited by 1
Medical Management of Cushing’s Syndrome
Dang, C. N., & Trainer, P. J. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_13 · Cited by 1
Pituitary-directed medical treatment of Cushing’s disease
Arnaldi, G., Cardinaletti, M., Trementino, L., Tirabassi, G., & Boscaro, M. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.10 · Cited by 1
Novel therapeutic directions in Cushing’s syndrome
Levy, A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.2.199
National Cancer Institute (2020) · Definitions · doi:10.32388/eibzc3
Prevention, diagnosis and treatment of Nelson's syndrome
Sala, E., Ho, A. L., Azad, T. D., Veeravagu, A., & Katznelson, L. J. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.01.001
Modern views on Cushing’s disease treatment
Kadzharyan, V. G., & Soloviuk, O. O. (2018) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2018.02.125354
Morris, D. G., Grossman, A. B., & Nieman, L. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00015-0 · Cited by 3
Metadata
- Authors
- Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M.
- Affiliations
- University of Padua (IT)
- University at Buffalo, State University of New York (US)
- Venue
- Pituitary
- Published
- 2000-10
- Volume
- 3
- Issue
- 2
- Pages
- 55-59
- ISSN
- 1386-341X (ISSN-L)
- 1573-7403
- OpenAlex
- W130491512
- Cited by
- 41
- References
- 39
- Citations by year
- 2023: 1 · 2022: 1 · 2020: 1 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 4 · 2013: 2
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pituitary (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Keywords
- Cushing's disease, ritanserin, ketanserin, 5-HT2 receptor antagonist, serotonin, ACTH, urinary cortisol, Nelson's syndrome, serotonergic regulation, pituitary-dependent Cushing's disease, drug response
- MeSH terms
- Adolescent, Adrenocorticotropic Hormone, Adult, Cushing Syndrome, Female, Hormones, Humans, Hydrocortisone, Ketanserin, Long-Term Care, Male, Middle Aged, Nelson Syndrome, Serotonin Antagonists, Ritanserin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.